$ Value
$0
Shares
40,363
Price
$0
Filed
Aug 14
Insider
Name
Waheed Nadia
Title
Chief Medical Officer
CIK
0002023884
Roles
Transaction Details
Transaction Date
2025-08-12
Code
A
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
247,168
Footnotes
On August 12, 2025, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, in equal annual installments, beginning on February 11, 2026. | 7/48 of the shares underlying the option vest on September 11, 2025, and 1/48 of the shares underlying the option vest monthly thereafter through February 11, 2029.
Filing Info
Waheed Nadia's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-02-20 | OCUL | ▼ | $27K |
| 2026-02-12 | OCUL | ▼ | $71K |
| 2026-01-02 | OCUL | A | $0 |
| 2026-01-02 | OCUL | A | $0 |
| 2025-08-12 | OCUL | A | $0 |
| 2025-08-12 | OCUL | A | $0 |
| 2025-06-02 | OCUL | ▼ | $112K |
Other Insiders at OCUL (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| LINDSTROM RICHARD L MD | $461K | — | 2026-02-20 |
|
Heier Jeffrey S.
Chief Scientific Officer
|
— | $25K | 2026-02-23 |
|
Dugel Pravin
See Remarks
|
— | $1.3M | 2026-04-09 |
|
Notman Donald
Chief Operating Officer
|
— | $205K | 2026-02-12 |
|
Kaiser Peter
Chief Development Officer
|
— | $23K | 2026-02-23 |
|
Nayak Sanjay
Chief Strategy Officer
|
— | $108K | 2026-02-23 |
|
Waheed Nadia
Chief Medical Officer
|
— | $98K | 2026-02-20 |
|
Robinson David Wayne
Global CCO
|
— | — | 2026-01-21 |